Journal of Clinical Epidemiology
Volume 58, Issue 1 , Pages 26-40 , January 2005

A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty

,Accepted 15 March 2004.

References 

  1. Smith RE. The failings of NICE: time to start work on version 2. BMJ. 2000;321:1363–1364
  2. Fletcher RH. Evaluation of interventions. J Clin Epidemiol. 2002;55:1183–1190
  3. Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med. 1987;6:371–388
  4. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98
  5. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ. 1995;311:1356–1359
  6. National Health and Medical Research Council . How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines. Canberra: NHMRC; 2000;Available at: http://www.nhmrc.gov.au/publications/pdf/cp69.pdf
  7. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68–S80
  8. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54:253–262
  9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  10. Deeks JJ, Altman DG. Effect measures for meta-analysis of trials with binary outcomes. In:  Egger M,  Davey Smith G,  Altman DG editor. Systematic reviews in health care: meta-analysis in context. 2nd ed.. London: BMJ Publishing Group; 2001;
  11. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17:1923–1942
  12. Thompson SG, Smith TC, Sharp SJ. Investigation underlying risk as a source of heterogeneity in meta-analysis. Stat Med. 1997;16:2741–2758
  13. Ioannidis JPA, Chew P, Lau J. Standardized retrieval of side effects data for meta-analysis of safety outcomes: a feasibility study in acute sinusitis. J Clin Epidemiol. 2002;55:619–626
  14. Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res. 2002;2:367–379
  15. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS Version 1.4. User manual. Cambridge: MRC Biostatistics Unit; 2000;
  16. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res. 2002;11:491–512
  17. Cooper NJ, Abrams KR, Sutton AJ, Turner D, Lambert PC. A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. J R Stat Soc Ser A. 2003;166:389–405
  18. Singer DE. Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiol. 1993;3:563–567
  19. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with nonrheumatic atrial fibrillation. BMJ. 2001;322:321–326[Erratum in: BMJ. 2001;322: 587.]
  20. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). The Cochrane Library, Issue 3, 2000:CD001927. Oxford: Update Software.
  21. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of randomized trials. J Clin Epidemiol. 1994;47:881–889
  22. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10:277–303
  23. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315–328
  24. Glasziou PP, Bromwich S, Simes RJ, AUS-TASK Group . Australian arm of International tPA/SK Mortality Trial. Quality of life six months after myocardial infarction treated with thrombolytic therapy. Med J Aust. 1994;161:532–536
  25. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed.. Oxford: Oxford University Press; 1997;
  26. Stroke Prevention in Atrial Fibrillation investigators . Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med. 1992;116:1–5
  27. Stroke Prevention in Atrial Fibrillation investigators . Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6–12
  28. Greenland S. Quantitative methods in the review of epidemiological literature. Epidemiol Rev. 1987;9:1–30
  29. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1–134
  30. Draper D. Assessment and propagation of model uncertainty. J R Stat Soc Ser B. 1995;57:45–97
  31. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105–3124
  32. Eddy DM, Hasselblad V, Shachter R. Meta-analysis by the confidence profile method. San Diego: Academic Press; 1992;
  33. Straus SE, McQuay H, Moore RA, Sackett DL. A proposed patient-centred method of delivering information about the risks and benefits of therapy: the likelihood of being helped versus harmed. Presented at Systematic Reviews: Beyond the Basics, Oxford, January 1999. Abstract available at http://www.ihs.ox.ac.uk/csm/talks.html#p29.
  34. McAlister FA. Applying the results of systematic reviews at the bedside. In:  Egger M,  Davey Smith G,  Altman DG editor. Systematic reviews in health care: meta-analysis in context. 2nd ed.. London: BMJ Publishing Group; 2001;
  35. Margitic SE, Morgan TM, Sager MA, Furberg CD. Lessons learned from a prospective meta-analysis. J Am Geriatr Soc. 1995;43:435–439
  36. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 1999;8:269–274
  37. Li W, Girard P, Boissel JP, Gueyffier F. The calculation of a confidence interval on the absolute estimated benefit for an individual patient. Comput Biomed Res. 1998;31:244–256
  38. Thompson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956–962[Erratum in: Lancet 2000; 355:1466.]
  39. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ. 2004;328:371–376
  40. McDonagh MS, Whiting PF, Wilson PM, Sutton AJ, Chestnutt I, Cooper J, et al. Systematic review of water fluoridation. BMJ. 2000;321:855–859
  41. Thompson DC, Rivara FP, Thompson RS. Helmets for preventing head and facial injuries in bicycling. Cochrane Library. Issue 4. Oxford: Update Software; 1999;
  42. Robinson D. Head injuries and bicycle helmet laws. Accid Anal Prev. 1996;28:463–475
  43. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511
  44. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412[Erratum in: N Engl J Med 1993;328: 148.]
  45. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349–355
  46. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;333:175–179
  47. Stroke Prevention in Atrial Fibrillation investigators . Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527–539
  48. EAFT (European Atrial Fibrillation Trial) Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255–1262
  49. Baker RN. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease: report of the Veterans Administration Cooperative Study of Atherosclerosis. Neurology. 1961;11:132–138
  50. Enger E, Boyesen S. Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. Acta Med Scand Suppl. 1965;438:1–61
  51. McDowell F, McDevitt E, Wright IS. Anticoagulant therapy: five years experience with the patient with an established cerebrovascular accident. Arch Neurol. 1963;8:209–214
  52. Altman R, Boullon F, Rouvier J, Raca R, De la Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1976;72:127–129
  53. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;331:1242–1245
  54. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322:428–432
  55. Harvald B, Hilden T, Lund E. Long-term anticoagulant therapy after myocardial infarction. Lancet. 1962;280:626–630
  56. Bjerkelund CJ. Therapeutic level in long-term anticoagulant therapy after myocardial infarction: its relation to recurrent infarction and sudden death. Am J Cardiol. 1963;1:158–163
  57. Loeliger EA, Hensen A, Kroes F, van Dijk LM, Fekkes N, de Jonge H, et al. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand. 1967;182:549–566
  58. Meuwissen OJAT, Vervoorn Ac, Cohen O, Jordan FLJ, Nelemans FA. Double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand. 1969;186:361–368
  59. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147–152
  60. White RH, McCurdy SA, von Marensdorff H, Woodruff DE, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. Ann Intern Med. 1989;111:730–737
  61. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood. 1990;75:344–349
  62. Bynum LJ, Wilson JE . Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med. 1979;67:553–556
  63. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855–858
  64. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189–194
  65. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676–1681
  66. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260–1264
  67. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol. 1983;51:1537–1541
  68. DiSeva VJ, Collins JJ, Cohn LH. Hematological complications with the St. Jude valve and reduced-dose coumadin. Ann Thorac Surg. 1989;48:280–283
  69. Fitzpatrick MA, McCone F. An audit of anticoagulation and endocarditis prophylaxis after heart valve surgery. N Z Med J. 1991;104:85–88
  70. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–152
  71. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med. 2002;21:1601–1623

PII: S0895-4356(04)00170-2

doi: 10.1016/j.jclinepi.2004.03.015

Journal of Clinical Epidemiology
Volume 58, Issue 1 , Pages 26-40 , January 2005

Article Tools

* Image Usage & Resolution